drugset / Trial / NCT02434770
Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine
Phase 3
Completed
750 enrolled
PATH
Beijing Bio-Institute Biological Products Co., Ltd., formerly Beijing TiantanBio · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
The purpose of this study will be to evaluate whether a bivalent oral polio vaccine (bOPV) manufactured by Beijing Bio-Institute Biological Products Co., Ltd (BBIBP) has a similar immunogenicity profile to a WHO prequalified bOPV.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-06-17
- Completion
- 2016-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBIBP Bivalent Oral Poliomyelitis Vaccine | Vaccine | 0.1 ml | Oral |
| Comparator | BioFarma Bivalent Oral Poliomyelitis Vaccine | Vaccine | 0.1 ml | Oral |